Zheng Z, Chen C, Jiang L, et al. - Researchers here addressed the metastatic pattern of the gastrointestinal neuroendocrine neoplasm (GI-NEN). Using the Surveillance, Epidemiology, and End Results (SEER) database (SEER-9 registry) from 1973 to 2015, they obtained the data. From the SEER-18 registry from 1 January 2010 to 31 December 2015, they obtained data with additional treatment fields of GI-NEN. They included a total of 14,685 GI-NEN patients and performed statistical analyses with SPSS 25.0, the Intercooled Stata SE 15.0, and GraphPad Prism 7. Observations revealed an increase in the incidence of GI-NENs from 0.51 per 100,000 patients in 1973 to 6.20 per 100,000 patients in 2015. Of them, 2,003 patients were diagnosed at stage IV GI-NEN, including 1,459 (72.84%) patients with liver metastasis, 144 (7.19%) lung metastasis, 115 (5.74%) bone metastasis, and 27 (1.35%) brain metastasis. The risk of metastasis was highest among cases with esophageal NEN (52.68%). For patients with liver, lung, bone, and brain metastasis, the median survival was 38, 6, 9, and 2 months, respectively. They identified a higher risk of concurrent existence of bone and brain metastasis in the presence of lung or liver metastasis than those without and hence screening for the same is recommended in the GI-NEN patients if they have lung or liver metastasis.